Skip to content
    CI
    Earnings call· Mar 2025(Q1 FY25)

    Cigna Group Q1 FY25 earnings call CI

    May 2, 2025 Source

    Executive summary

    The Cigna Group Q1 FY25 — Strong Start, Raised FY25 EPS Outlook

    The Cigna Group delivered strong Q1 FY25 results, exceeding expectations with robust revenue and adjusted EPS growth, leading to an increased full-year EPS outlook. The company demonstrated resilience in a dynamic environment, driven by its Evernorth and Cigna Healthcare platforms, while making strategic investments and addressing healthcare challenges through enhanced access, support, value, accountability, and transparency initiatives.

    Highlights

    5

    • Total revenue reached $65.5 billion in Q1 FY25.

    • Adjusted earnings per share grew to $6.74 in Q1 FY25.

    • Full year 2025 adjusted EPS guidance was raised to at least $29.60.

    • Evernorth Specialty and Care Services revenue grew 19% to $23.9 billion.

    • Cigna Healthcare Select segment customers grew 9% year-over-year.

    Concerns

    3

    • Net after-tax special item charges of $229 million or $0.84 per share were recorded in Q1 FY25.

    • Medical cost trends are expected to remain elevated in 2025.

    • GLP-1s represent about 3% of total healthcare costs for the average employer providing access.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year 2025 Adjusted EPS
    at least $29.60
    high materiality
    High
    Long-term Compounded EPS Growth
    10% to 14%
    high materiality
    High
    Full-year 2025 Evernorth Pretax Adjusted Earnings
    at least $7.2 billion
    medium materiality
    High
    Full-year 2025 Cigna Healthcare Pretax Adjusted Earnings
    at least $4.125 billion
    medium materiality
    High
    Full-year 2025 Medical Care Ratio
    83.2% to 84.2%
    high materiality
    High
    Q2 Adjusted EPS
    slightly below 25% of the full year outlook
    medium materiality
    Medium
    Q2 Cigna Healthcare Adjusted Earnings
    slightly above 25% of the full year outlook
    medium materiality
    Medium
    Q2 Medical Care Ratio
    towards the low end of the full year range
    medium materiality
    Medium
    Debt-to-capitalization ratio
    lower at year-end
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Evernorth
    Evernorth delivered strong results, with double-digit revenue growth led by Pharmacy Benefit Services and Specialty and Care Services. Specialty and Care Services normalized earnings grew 11% YoY, reflecting demand for specialty drugs and biosimilar adoption. Pharmacy Benefit Services showed solid growth due to client retention and new business wins.
    Pretax adjusted earnings growth: 5% YoYSpecialty and Care Services revenue: $23.9 billionSpecialty and Care Services revenue growth: 19% YoYSpecialty and Care Services normalized pretax adjusted earnings growth: 11% YoYPharmacy Benefit Services pretax adjusted earnings: $544 millionPharmacy Benefit Services pretax adjusted earnings growth: 4% YoYPharmacy Benefit Services revenue growth: 14% YoYSpecialty script volumes: mid-teens growthExpress Scripts prescriptions: over 2 billion this yearExpress Scripts savings for clients: $38 billion last yearAccredo patient satisfaction rates: 97%
    		$53.7 billion——$1.4 billion
    Cigna Healthcare
    Cigna Healthcare earnings exceeded expectations with 9% revenue growth, powered by strong rate execution. The Select segment showed strong customer growth. The reported MCR of 82.2% includes a 100 bps increase due to the later timing of the Medicare divestiture. Underlying performance was favorable to expectations.
    Medical Care Ratio (MCR): 82.2%Select segment customer growth: 9% YoYSelect segment market share: 7%GLP-1s as % of total healthcare costs (for employers providing access): 3%
    		$14.5 billion9%—$1.3 billion

    Operational metrics

    27
    Adjusted EPS
    $6.74
    Q1 FY25

    Reported adjusted earnings per share.

    Total Revenue
    $65.5 billion
    Q1 FY25

    Consolidated total revenue.

    Net after-tax special item charges
    $229 million
    Q1 FY25

    Related to a strategic optimization program.

    Net after-tax special item charges per share
    $0.84
    Q1 FY25

    Related to a strategic optimization program.

    Strategic optimization program charge
    $163 million
    Q1 FY25

    After-tax charge related to the program itself.

    Strategic optimization program charge per share
    $0.63
    Q1 FY25

    After-tax charge per share related to the program itself.

    Evernorth Specialty and Care Services income as % of company income
    30%
    today

    Represents current contribution to company income.

    Express Scripts income as % of company income
    30%
    today

    Represents current contribution to company income.

    Cigna Healthcare income as % of company income
    40%
    today

    Represents current contribution to company income.

    Express Scripts prescriptions processed
    over 2 billion
    this year

    Expected volume for the year.

    Express Scripts prescriptions that are cost-effective generics
    around 90%
    this year

    Percentage of total prescriptions.

    GLP-1 market size (U.S.)
    exceed $100 billion
    by 2030

    Expected market size.

    Americans expected to be on GLP-1 medication
    1 in 10
    by 2030

    Expected penetration rate.

    EnCircleRx members enrolled
    approximately 9 million
    current

    Number of members eligible for the program.

    Evernorth book of business employer coverage for weight management
    just north of 50%stable from 2024
    current

    Percentage of employers providing coverage for weight management.

    Cigna Healthcare book of business employer coverage for weight management
    15% to 20%stable from 2024
    current

    Percentage of employers providing coverage for weight management, lower due to smaller average employer size.

    Express Scripts retention
    mid-90s or betterconsistent with prior years
    2026 selling season

    Expected client retention rate.

    Average employer's healthcare spend in specialty drugs
    about 20%
    current

    Includes drugs covered under prescription and medical benefits.

    Specialty drug spend subject to competition from biosimilars and generics
    $100 billion
    by 2030

    Expected market opportunity for biosimilars and generics.

    Select segment funding mix (fully insured)
    a little bit over half
    current

    Proportion of clients choosing fully insured offerings.

    Select segment funding mix (ASO/self-funded)
    a little bit under half
    current

    Proportion of clients choosing ASO or self-funded offerings, with essentially 100% buying stop-loss.

    Debt-to-capitalization ratio
    43.1%
    as of March 31

    Reported ratio at quarter-end.

    Shares repurchased
    8.2 million
    as of May 1

    Total shares repurchased.

    Share repurchase value
    $2.6 billion
    as of May 1

    Total value of shares repurchased.

    Medicare business MCR impact
    100 bps
    Q1 FY25

    Increase to reported MCR due to later timing of Medicare divestiture.

    Medicare business earnings impact
    less than $20 million
    Q1 FY25

    Marginal earnings impact from carrying the business longer than anticipated.

    Cigna Healthcare MCR (excluding Medicare impact)
    about 80%
    Q1 FY25

    Implied MCR for ongoing businesses after adjusting for Medicare divestiture timing.

    Industry KPIs

    8
    MetricValueDetails
    Utilization trendselevated
    Medical loss care ratio82.2%%
    Client retention new winsmid-90s or better%
    Pharmacy scripts specialtymid-teens% growth
    Membership covered lives by line3 millioncustomers
    Segment revenue operating income$53.7 billionUSD
    Adjusted EPS EBITDA leverage guidanceat least $29.60USD
    Medical cost trend vs pricing assumptionelevated%

    Product announcements

    2
    ProductTypeDetails
    EnreachRxlaunch
    ENGUIDElaunch

    Deals & partnerships

    1
    HCSCSale of Medicare businesses

    Completed the divestiture of Medicare businesses to HCSC on March 19, about a month later than financial planning assumptions.

    Risks & headwinds

    4
    Elevated Medical Cost Trends2025

    Consistent with expectations in most categories (specialty, behavioral); some moderation in surgical activity and OB services.

    Mitigation: Prudently maintained MCR assumptions for the full year; action plan to improve stop-loss margins.

    GLP-1 Affordability and Access ChallengesOngoing

    GLP-1s represent about 3% of total healthcare costs for average employer providing access; market size expected to exceed $100 billion in U.S. by 2030.

    Mitigation: Comprehensive GLP-1 strategy with EnCircleRx, EnreachRx, and ENGUIDE solutions to address access, affordability, clinical safety, and lifestyle changes.

    Adverse Arkansas LegislationOngoing

    Bill picks and chooses winners, uses licensure to limit choice, commerce, and free market. Expected to decrease access, reduce choice, erode quality, and increase costs for citizens.

    Mitigation: Opposing the construct and intent of the bill; engaging in fact-based discussions; activating clients' voice; embracing actionable transparency; continued innovation; potential regulatory/litigious steps.

    Dynamic Economic Environment2025

    Economy is a bit uncertain and less stable, though no dislocation seen in client portfolio or enrollment levels thus far in Q1.

    Mitigation: Full year outlook and ranges contemplate market dynamism; prudent to maintain planning assumptions.

    What to watch in Q2 FY25

    5

    Stop-loss margin improvement

    Next quarter (Q2 FY25)
    CurrentTracking to expectations for Q1 FY25
    TargetContinued progress towards recouping margin over 2025-2026 renewal cycles

    Why it matters

    Critical for Cigna Healthcare's profitability and overall financial performance, especially given prior pressures.

    Our plan and expectation is to recoup the margin through the '25 and '26 season. So over the 2-year horizon, profitable book of business, less profitable than it's historically been. We'll recoup throughout the course of this year, largely in the second half and then recoup further in 2026.

    Q&A highlights

    6

    What are Cigna's negotiation opportunities for GLP-1s, what are current coverage levels, and what are your thoughts on the Arkansas legislation?

    Brian discussed Cigna's comprehensive GLP-1 strategy (EnCircleRx, EnreachRx, ENGUIDE) focusing on access, affordability, clinical safety, and lifestyle changes. He noted 50%+ employer coverage for weight management in Evernorth and 15-20% in Cigna Healthcare. David opposed the Arkansas bill, stating it limits choice, commerce, and free markets, leading to decreased access, reduced choice, and increased costs for citizens.

    “We oppose both the construct and the intent of the bill. Having said that, I'd reinforce that Arkansas is a relatively small market for the Cigna Group.”

    asked by Lisa Gill · answered by David Cordani

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Optimization Program and Special Charges

    Cigna initiated a strategic optimization program in Q1 2025 to further advance ongoing efficiency initiatives, leveraging scale, technology, and innovation for long-term growth. This program resulted in net after-tax special item charges of $229 million, or $0.84 per share, including a $163 million ($0.63 per share) charge related to the program itself. These actions underscore the company's commitment to continuous improvement in a dynamic healthcare landscape.

    02

    Comprehensive GLP-1 Strategy and Innovation

    GLP-1 drugs are identified as a significant trend driver, representing approximately 3% of total healthcare costs for employers providing access. Cigna is addressing the challenges of affordability, access, and clinical coordination through a comprehensive suite of solutions. This includes EnCircleRx, which now covers 9 million members, and new innovations like EnreachRx, a high-touch patient support clinical model, and ENGUIDE, a specialized GLP-1 pharmacy launching next month, designed to enhance clinical care and affordability.

    03

    Evernorth's Strong Growth Drivers

    Evernorth delivered strong Q1 results with double-digit revenue growth in Pharmacy Benefit Services and Specialty and Care Services. Specialty pharmacy volumes increased mid-teens, particularly in the Medicare book of business, benefiting from the structural shift towards complex specialty medications. Increased adoption of biosimilars, including interchangeable HUMIRA and the upcoming STELARA biosimilar, also contributed to growth and cost savings for clients and patients.

    04

    Cigna Healthcare Performance and Stop-Loss Improvement

    Cigna Healthcare exceeded expectations with 9% revenue growth, driven by strong rate execution and 9% year-over-year customer growth in the under 500 Select segment. The company is confident in its action plan to improve margins on its stop-loss products over the 2025 and 2026 renewal cycles, with early 2025 indicators tracking to expectations. Medical cost trends remained elevated in most categories, consistent with expectations, though some moderation was observed in surgical and OB services.

    05

    Customer-Focused Commitments and Transparency

    Cigna announced five key commitments to improve the healthcare system: enhancing access, providing better support, lowering costs (value), increasing accountability (tying leadership compensation to customer satisfaction), and improving transparency. These proactive commitments have been positively received by stakeholders, demonstrating the company's resolve to build a more sustainable healthcare model and publicly share progress on these initiatives.

    06

    Disciplined Capital Management and Divestiture Impact

    The company completed the divestiture of its Medicare businesses to HCSC on March 19, which modestly benefited Q1 earnings but increased the reported Medical Care Ratio by 100 basis points due to the later timing of📎 the close. Cigna continues its disciplined capital management approach, having repurchased 8.2 million shares for approximately $2.6 billion as of May 1, and aims for a lower debt-to-capitalization ratio by year-end through debt paydown.

    AI-generated summary of the company’s earnings call. Not investment advice.